Mobix Labs, Inc. (NASDAQ:MOBX – Get Free Report) Director James J. Peterson sold 146,732 shares of the firm’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $1.04, for a total transaction of $152,601.28. Following the completion of the sale, the director now owns 2,115,574 shares of the company’s stock, valued at $2,200,196.96. The trade was a 6.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Mobix Labs Stock Down 2.9 %
Shares of MOBX stock traded down $0.03 on Monday, reaching $1.01. 242,466 shares of the company were exchanged, compared to its average volume of 805,081. The company has a debt-to-equity ratio of 0.23, a current ratio of 0.13 and a quick ratio of 0.09. The company has a 50-day moving average of $1.28 and a 200-day moving average of $1.12. The company has a market cap of $37.36 million, a price-to-earnings ratio of -0.76 and a beta of -0.31. Mobix Labs, Inc. has a one year low of $0.55 and a one year high of $3.62.
Mobix Labs (NASDAQ:MOBX – Get Free Report) last announced its quarterly earnings results on Tuesday, February 18th. The company reported ($0.52) earnings per share (EPS) for the quarter. Mobix Labs had a negative return on equity of 866.93% and a negative net margin of 437.57%. The firm had revenue of $3.17 million during the quarter.
Institutional Investors Weigh In On Mobix Labs
Mobix Labs Company Profile
Mobix Labs, Inc, a fabless semiconductor company, provides wireless and connectivity solutions for next generation communication systems, including C-Band and mmWave 5G and high bandwidth cable applications. Its products include True5G chipset solutions; true xero active optical cables and related products designed to deliver fiber optic connectivity for a range of applications, including 5G infrastructure, autonomous vehicles, Pro A/V, AR/VR, remote medical systems, and others; electromagnetic interference filters deployed in aerospace, military, defense, medical, and healthcare products.
Read More
- Five stocks we like better than Mobix Labs
- How to Profit From Value Investing
- How to Protect Your Portfolio When Inflation Is Rising
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- 3 Tech Stocks Defying Sector Weakness and Thriving in 2025
- Stock Sentiment Analysis: How it Works
- Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Receive News & Ratings for Mobix Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mobix Labs and related companies with MarketBeat.com's FREE daily email newsletter.